TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8251281
Drug: Doxapram 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 1.5 mg kg‐1
Study: 8251281
Drug: Pethidine 0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.33 mg kg‐1
Study: 30283171
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 3 mg (2 tablets)
Study: 30283171
Drug: Oral alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alprazolam 0.25 mg (2 tablets)
Study: 30283171
Drug: Placebo (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multivitamin tablet 2 tablets)
Study: 27376373
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) intravenous/subcutaneous
Study: 27376373
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) subcutaneous
Study: 27376373
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) intravenous
Study: 20595484
Drug: Topical nanofiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nanofiber nitric oxide (NO) releasing patch (NOP)
Study: 20595484
Drug: Intramuscular meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meglumine antimoniate (Glucantime)
Study: 14732966
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of arnica and hydroxyethyl salicylate (HES) in ethanolic solution (Sportino Acute Spray)
Study: 7806733
Drug: Katz Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Katz Activities of Daily Living (ADL)
Study: 7806733
Drug: Older Americans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older Americans Resources and Services Instrumental Activities of Daily Living (OARS-IADL)
Study: 7154618
Drug: muzolimine (loop-diuretic)
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine (loop-diuretic) for 6 weeks
Study: 30659924
Drug: Genotype-tailored lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genotype-tailored lansoprazole daily for 24 weeks
Study: 30659924
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of open-label oral lansoprazole
Study: 21739168
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg i.v. twice weekly after surgery
Study: 21739168
Drug: Cilengitide 500
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 500 mg i.v. (day -8, -4, -1)
Study: 21739168
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg i.v. (day -8, -4, -1)
Study: 21739168
Drug: Cilengitide (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide (as a single agent)
Study: 19409340
Drug: Early orthodontic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early orthodontic treatment using Twin-block appliance
Study: 17443132
Drug: Zolpidem (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (7.5 mg) + Placebo (P)
Study: 17443132
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg) or (500 mg) + Zolpidem (7.5 mg)
Study: 9686324
Drug: BT563 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (10 mg/d from day 0 until day 12)
Study: 8004363
Drug: ket 1
Normalized name: Monoket 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ket 1 mg/kg + mid 0.1 mg/kg, max. 5 mg
Study: 8004363
Drug: ket 1
Normalized name: Monoket 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ket 1 mg/kg + mid 0.05 mg/kg, max. 2.5 mg
Study: 8004363
Drug: ket 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ket 0.75 mg/kg + mid 0.1 mg/kg, max. 5 mg
Study: 2806201
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml dairy cream and 23 g protein (casein)
Study: 2806201
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml dairy cream
Study: 2806201
Drug: 23 g
Normalized name: PEG-23 GLYCERYL DISTEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 g casein
Study: 1105777
Drug: Genuine roentgen
Normalized name: Genuine First Aid - Auto First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genuine roentgen radiation treatment
Study: 25908360
Drug: Nomogram for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram for calculating maximum dose of local anaesthetic
Study: 11029598
Drug: ACE-inhibition (quinapril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibition (quinapril, 10 mg day-1)
Study: 2492746
Drug: Water solution
Normalized name: CVS Live Better Gripe Water Solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water solution
Study: 27632067
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer Solution (LR; placebo)
Study: 24192120
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitor (ACEI)
Study: 22093311
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg, s.c., 12 hours before and after surgery, then once daily for 7 consecutive days)
Study: 22093311
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg, s.c.)
Study: 2550646
Drug: Enalapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ACE inhibitor)
Study: 14636907
Drug: GFR >/=90
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR >/=90 ml/min/1.73 m(2)
Study: 14636907
Drug: Lowest hematocrit-GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest hematocrit-GFR risk class (hematocrit >/=36%, GFR >/=90 ml/min/1.73 m(2))
Study: 14636907
Drug: Highest risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest risk class (hematocrit <33%, GFR <60 ml/min/1.73 m(2))
Study: 7812924
Drug: BCG prophylactic
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG prophylactic therapy (40 mg monthly for 12 times) - Group A
Study: 28877896
Drug: Potassium- and
Normalized name: bendroflumethiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium- and magnesium-enriched salt (K/Mg salt)
Study: 26735058
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy with a pulsed wave form, visible ray, wave length of 632.8 nm, 30 mW peak power, applied for 80 seconds (4J/cm2), 12 appointments (3 weekly in alternated days)
Study: 28169916
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg E4
Study: 3530933
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2V
Study: 26224299
Drug: Food, Activity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food, Activity, and Breastfeeding (FAB) intervention; Combination (FAB and Sleep)
Study: 26224299
Drug: Sleep intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep intervention; Combination (FAB and Sleep)
Study: 24472479
Drug: RCT (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT (standard chemotherapy)
Study: 24472479
Drug: Off-trial (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-trial (standard chemotherapy)
Study: 21114776
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate 1g + 15% magnesium sulphate 1g diluted in 100 mL of dextrose 5%
Study: 18080748
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil; 600/40/600 mg/m(2))
Study: 18080748
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (CMF or EC depending on node status)
Study: 9343270
Drug: Budesonide (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (0.4 mg/day)
Study: 8238327
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g AA.kg LBM‐1.day‐1
Study: 8238327
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g AA.kg LBM‐1.day‐1
Study: 8238327
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g AA.kg LBM‐1.day‐1
Study: 1974071
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg
Study: 28225505
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg/d
Study: 21742443
Drug: Chestnut tannins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chestnut tannins 10 g/kg diet (CT10)
Study: 21742443
Drug: Chestnut tannins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chestnut tannins 5 g/kg diet (CT5)
Study: 18402729
Drug: Finasteride, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride, a potent 5 alpha‐reductase inhibitor, measured in human plasma
Study: 16192529
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen sodium 1100 mg
Study: 12614467
Drug: IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2b 5 MU daily for 4 weeks followed by IFN (5 MU tiw) and ribavirin (1000‐1200 mg/day) for 48 weeks (Group A)
Study: 12614467
Drug: IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2b 5 MU tiw for 4 weeks followed by IFN (5 MU tiw) and ribavirin (1000‐1200 mg/day) for 48 weeks (Group B)
Study: 2508167
Drug: Cocaine infusion
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine infusion (40 mg)
Study: 2508167
Drug: Instructed placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructed placebo (saline infusion with prior instruction)
Study: 184309
Drug: DBcAMP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DBcAMP infusion at 10 mg/min for 20 min
Study: 184309
Drug: DBcAMP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DBcAMP infusion at 20 mg/min for 20 min
Study: 25393158
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid for Vascular Outcome Reduction in Transplant trial medication
Study: 25393158
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor and statin
Study: 25393158
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and angiotensin-converting enzyme inhibitor
Study: 18308881
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) - 30 maximal inspirations daily
Study: 2371367
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 mg)
Study: 9193361
Drug: PIXY321 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIXY321 750 micrograms/m2/d divided into two subcutaneous doses
Study: 9193361
Drug: GM‐CSF 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF 250 micrograms/m2/d as a 2‐hour intravenous infusion
Study: 1551960
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase support with a single dose of human chorionic gonadotrophin
Study: 3925179
Drug: No Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Heparin (Control)
Study: 30019627
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 µg subcutaneously twice daily
Study: 27054828
Drug: Mindfulness in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness in schools curriculum (8 lessons, once weekly)
Study: 25175601
Drug: Incabotulinum toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incabotulinum toxin type A (iBTA) before conventional rehabilitation treatment (CT)
Study: 25175601
Drug: Saline before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline before conventional rehabilitation treatment (CT)
Study: 22923162
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) + daily dietary supplement containing arginine, Vinitrox, collagen, methyl‐sulfonyl‐methane, vitamin C, and bromelain
Study: 21462480
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction programme (dietary modifications of 1200-1400 kcal/day, physical activity modifications, behaviour therapy)
Study: 9986921
Drug: CRH administration
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH administration during SWS (protocol A)
Study: 9986921
Drug: CRH administration
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH administration during wakefulness (protocols B and C)
Study: 9986921
Drug: GHRH pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH pre-treatment
Study: 9986921
Drug: Baseline condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline condition (saline treatment only, protocol D)
Study: 7569030
Drug: Three fractions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three fractions per day (multiple fractions per day, MFD) with misonidazole 1 g/m2/day
Study: 1887473
Drug: Dapsone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100 mg) every 12 h for 6 weeks
Study: 1887473
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets every 12 h for 6 weeks
Study: 6415182
Drug: Formalin‐inactivated vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated vaccine (doses not specified)
Study: 6415182
Drug: Formalin‐inactivated vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated vaccine
Study: 25135724
Drug: Peg‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2b plus adefovir dipivoxil (10 mg daily) for 52 weeks
Study: 25135724
Drug: Peg‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2b alone (1.5 μg/kg once weekly) for 52 weeks
Study: 22685578
Drug: Minocycline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (400 mg)
Study: 22685578
Drug: Capsaicin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (10 µg)
Study: 17915972
Drug: Family intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family intervention approach according to the McMaster Model and maintenance of the anti‐depressant drug at the same dosage
Study: 17915972
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase and clinical management
Study: 16143228
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg elemental calcium, 400 IU Vitamin D3)
Study: 16143228
Drug: Estrogen patches
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen patches (3.9 mg estradiol) and progesterone (100 mg/day)
Study: 10189539
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente (UL) insulin
Study: 10189539
Drug: Twice-daily NPH
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily NPH insulin
Study: 2407023
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg tablet twice daily)
Study: 2407023
Drug: Trimethoprim-sulfamethoxazole (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (double strength tablet twice daily)
Study: 8813873
Drug: Mianserin 10
Normalized name: mianserin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 10 mg
Study: 341944
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg + Alcohol
Study: 341944
Drug: Mianserin 10
Normalized name: mianserin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 10 mg + Alcohol
Study: 31783854
Drug: Monthly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly feedback
Study: 28173780
Drug: Internet-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet-administered intervention (6-month access)
Study: 25884350
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administered within 1 hour before skin incision
Study: 25884350
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administered after skin incision
Study: 23986159
Drug: Calcipotriol 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 0.005% (50 mcg/gm) applied twice a day
Study: 23986159
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar 6% and salicylic acid 3% ointment applied at nighttime
Study: 17565326
Drug: Alemtuzumab induction
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab induction with tacrolimus monotherapy
Study: 22390816
Drug: Basiliximab induction
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab induction with tacrolimus and mycophenolate mofetil (MMF) therapy
Study: 17848796
Drug: Individualized aerobic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized aerobic exercise training combined with conventional spa therapy
Study: 14766772
Drug: Antioxidants (all‐rac‐alpha‐tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (all‐rac‐alpha‐tocopherol 800 mg/day for 3 weeks and alpha‐lipoic acid 600 mg/day for 2 weeks)
Study: 11354934
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 13 weeks
Study: 11354934
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily, fluoxetine 90 mg weekly, or placebo during continuation therapy
Study: 11354934
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (Fluoxetine 20 mg daily, fluoxetine 90 mg weekly)
Study: 11199947
Drug: Fluoxetine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (any dosage)
Study: 8150114
Drug: Nafarelin acetate
Normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nafarelin acetate (200 micrograms twice daily)
Study: 8150114
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (1 mg/d SC)
Study: 27281802
Drug: Daily snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snack made from leafy green vegetables, fruit, and milk
Study: 27281802
Drug: Low-micronutrient vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-micronutrient vegetables (e.g., potato and onion)
Study: 27281802
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (leafy green vegetables, fruit, and milk)
Study: 20394026
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (CII)
Study: 18503925
Drug: Intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent subcutaneous insulin therapy
Study: 15567882
Drug: Levonorgestrel 0.75
Normalized name: levonorgestrel 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 0.75 mg given 24 h apart
Study: 15567882
Drug: Levonorgestrel 0.75
Normalized name: levonorgestrel 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 0.75 mg given 12 h apart
Study: 8690809
Drug: High glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High glucagon with insulin and GH
Study: 8690809
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of GH and insulin
Study: 2009148
Drug: Delapril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril (15 mg single dose)
Study: 2009148
Drug: Captopril (18.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (18.75 mg single dose)
Study: 2009148
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 mg single dose)
Study: 2009148
Drug: Delapril (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril (30 mg/day for 1 week)
Study: 2009148
Drug: Captopril (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5 mg/day for 1 week)
Study: 2009148
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/day for 1 week)
Study: 2009148
Drug: Delapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril (4 weeks treatment)
Study: 2009148
Drug: Captopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (4 weeks treatment)
Study: 2009148
Drug: Enalapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (4 weeks treatment)
Study: 6800465
Drug: 1250 APTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 APTT units of low‐molecular‐weight heparin every 12 hours